--- title: Why Raising 'Good' Cholesterol Doesn't Always Help the Heart description: Some drugs can successfully lower bad LDL cholesterol levels, but finding a medication that boosts good HDL cholesterol hasn’t been as easy canonical: https://time.com/4279691/hdl-cholesterol-drugs-heart/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2016-04-04T18:33:17.000Z article:modified_time: 2026-02-22T16:24:48.609Z article:section: Health og:title: Why Raising 'Good' Cholesterol Doesn't Always Help the Heart og:description: Some drugs can successfully lower bad LDL cholesterol levels, but finding a medication that boosts good HDL cholesterol hasn’t been as easy og:url: https://time.com/4279691/hdl-cholesterol-drugs-heart/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blta936e409eb500cb9/69888d95428a9e64cdcd20fa/heart-organ.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 4180 og:image:height: 2351 og:image:alt: heart organ og:type: article twitter:card: summary_large_image twitter:title: Why Raising 'Good' Cholesterol Doesn't Always Help the Heart twitter:description: Some drugs can successfully lower bad LDL cholesterol levels, but finding a medication that boosts good HDL cholesterol hasn’t been as easy twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blta936e409eb500cb9/69888d95428a9e64cdcd20fa/heart-organ.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Why Raising 'Good' Cholesterol Doesn't Always Help the Heart > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=e9a19ea7-1723-43d4-8678-f0317ece1688&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=e9a19ea7-1723-43d4-8678-f0317ece1688&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=e9a19ea7-1723-43d4-8678-f0317ece1688&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 4, 2016 6:33 PM UTC  Human heart, illustration Human heart, illustration Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 4, 2016 6:33 PM UTC Doctors and drug companies don’t like to report negative results, but when it comes to medications that raise HDL, or good cholesterol levels, they’re getting used it. In a presentation at the American College of Cardiology, researchers report that the latest study involving such a drug, made by Eli Lilly, didn’t seem to reduce heart disease events. The study involved an experimental drug called evacetrapib, the third drug of its class designed to raise HDL levels. In studies, people with higher HDL levels tend to have lower rates of heart disease; exercise also raises HDL, and heart doctors believe that HDL can counteract the build-up of harmful cholesterol in heart vessels. More than 12,000 people at high risk of heart disease—most of whom were overweight or obese, had high blood pressure, had diabetes or had experienced a heart event—were randomly assigned to take evacetrapib or placebo and were followed for 1.5 years. The drug significantly increased HDL levels in people who took it, by about 130%, and lowered LDL by 37%. But a year after starting the drug, there was little difference in the number of heart events between the two groups. That prompted the company and the researchers conducting the trial to stop the study early. Lilly also decided to stop developing the drug. “This drug did all the right things to lipids but didn’t do anything to morbidity and mortality from heart disease,” says Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic and chair of the steering committee for the study. **MORE:** [A Common Cholesterol Drug’s Safety Is In Question](http://time.com/3001573/a-common-cholesterol-drugs-safety-is-in-question/) That means that “it really does matter how you lower LDL,” he says. Statins and likely the [latest class of cholesterol lowering drugs](http://time.com/4279674/statins-heart-disease/), the PCSK9 inhibitors, work on the liver by boosting activity of the LDL receptors on the liver, which results in less LDL circulating in the blood. Evacetrapib works through a different pathway by making less LDL and building up more HDL. But how could a drug that lowered LDL and boosted HDL have such little effect on the heart? Nissen says it’s still not clear how evacetrapib affects cholesterol particles, but it’s possible that since LDL comes in different forms (some which are more damaging to the heart than others) evacetrapib may be pushing production of the more harmful type. Even with lower levels of LDL, there may still be sufficient blockage of heart vessels. The end result is no reduction in the risk of heart events. “In my opinion it’s now three strikes against this class of drugs,” says Nissen. “It’s time to move on.” But other pharmaceutical companies are still developing drugs to increase HDL levels in the hopes that this pathway will prove helpful for the heart. Time (and more research) will tell if their formulations are different enough to have an effect. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/4279691/hdl-cholesterol-drugs-heart/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/4279691/hdl-cholesterol-drugs-heart/"},"headline":"Why Raising 'Good' Cholesterol Doesn't Always Help the Heart","datePublished":"2016-04-04T18:33:17.000Z","dateModified":"2026-02-22T16:24:48.609Z","description":"A number of drugs can successfully lower bad cholesterol levels, but finding a medication that boosts good cholesterol hasn’t been as easy","url":"https://time.com/4279691/hdl-cholesterol-drugs-heart/","keywords":["Heart Disease","cholesterol"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blta936e409eb500cb9/69888d95428a9e64cdcd20fa/heart-organ.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blta936e409eb500cb9/69888d95428a9e64cdcd20fa/heart-organ.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"heart organ","caption":"heart organ","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/heart-disease/","name":"Heart Disease"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/4279691/hdl-cholesterol-drugs-heart/","name":"Why Raising 'Good' Cholesterol Doesn't Always Help the Heart"}}]}] ```